Metagenomi (MGX) to Post Earnings on Tuesday

Metagenomi (NASDAQ:MGX) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.5531) per share and revenue of $3.01 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:00 PM ET.

Metagenomi (NASDAQ:MGX) last released its earnings results on Monday, May 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). The firm had revenue of $1.25 million for the quarter, compared to analyst estimates of $5.90 million. Metagenomi had a negative return on equity of 51.23% and a negative net margin of 384.61%. On average, analysts expect Metagenomi to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Metagenomi Stock Performance

MGX traded up $0.01 during trading on Tuesday, reaching $1.23. The company had a trading volume of 26,696 shares, compared to its average volume of 209,142. Metagenomi has a 12-month low of $1.13 and a 12-month high of $3.95. The company has a market cap of $46.12 million, a price-to-earnings ratio of -0.53 and a beta of 0.66. The firm’s 50-day simple moving average is $1.25 and its 200 day simple moving average is $1.39.

Analyst Ratings Changes

Several brokerages have weighed in on MGX. Weiss Ratings lowered Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 23rd. Wells Fargo & Company dropped their price objective on Metagenomi from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Chardan Capital started coverage on shares of Metagenomi in a research note on Tuesday, July 7th. They set a “buy” rating and a $5.00 target price for the company. Finally, Wall Street Zen upgraded shares of Metagenomi from a “strong sell” rating to a “sell” rating in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Hedge Funds Weigh In On Metagenomi

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in shares of Metagenomi by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 305,908 shares of the company’s stock valued at $496,000 after buying an additional 14,018 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Metagenomi by 1,840.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock worth $36,000 after acquiring an additional 14,389 shares during the last quarter. Bank of America Corp DE increased its position in Metagenomi by 508.5% in the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after acquiring an additional 15,682 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of Metagenomi by 16.1% in the fourth quarter. Wells Fargo & Company MN now owns 118,410 shares of the company’s stock worth $192,000 after acquiring an additional 16,402 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Metagenomi during the third quarter worth approximately $64,000.

About Metagenomi

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.